Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy
Cussons AJ, Watts GF, Mori TA, Stuckey BG
The Journal of clinical endocrinology and metabolism · 133 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2009-07-22 · J Clin Endocrinol Metab · vol. 94 · número 10 · págs. 3842–3848
- Editorial
- Oxford University Press
- Citado
- 181 citas · más que el 98% de estudios similares · 9.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 37 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Liver Disease Diagnosis and Treatment · Ovarian function and disorders
- Palabras clave
- omega-3 fatty acids, polycystic ovary syndrome, hepatic steatosis, liver fat, non-alcoholic fatty liver disease, triglycerides, blood pressure, cardiovascular risk factors, women's health, 1H NMR, dietary supplementation, dyslipidemia, hypertriglyceridemia, hypercholesterolemia
- MeSH
- humans, polycystic ovary syndrome, fatty liver, obesity, protons, fatty acids, omega-3, magnetic resonance spectroscopy, administration, oral, drug administration schedule, cross-over studies, dietary supplements, adult, middle aged, female
4 autores
- Andrea J. Cussons🇦🇺 · autor de correspondenciaThe University of Western Australia; Royal Perth Hospital
- Gerald F. Watts🇦🇺The University of Western Australia; Royal Perth Hospital
- Trevor Anthony Mori🇦🇺The University of Western Australia; Royal Perth Hospital
- Bronwyn G. A. Stuckey🇦🇺The University of Western Australia; Royal Perth Hospital; Sir Charles Gairdner Hospital; Keogh Institute for Medical Research
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
There is an association between nonalcoholic fatty liver disease (NAFLD) and the polycystic ovary syndrome (PCOS). Marine-derived omega-3 fatty acids have favorable effects on cardiovascular risk and could reduce liver fat in NAFLD.
Objective
The primary aim of this study was to examine the effects of omega-3 fatty acids on liver fat in PCOS. The secondary aim was to assess their effects on traditional cardiovascular risk factors.
Design and setting
We conducted a randomized, crossover study at a tertiary cardiovascular research center.
Subjects
Twenty-five women with PCOS (mean age, 32.7 yr; mean body mass index, 34.8 kg/m(2)) participated in the study.
Intervention
We compared 4g/d of omega-3 fatty acids with placebo over 8 wk.
Main outcome measures
The primary outcome measure was hepatic fat content quantified using proton magnetic resonance spectroscopy. Secondary outcome measures included fasting lipids and blood pressure.
Results
Omega-3 fatty acids significantly decreased liver fat content compared with placebo [10.2 (1.1) vs. 8.4 (0.9)%; P = 0.022]. There was also a reduction in triglycerides [1.19 (1.03-1.47) vs. 1.02 (0.93-1.18) mmol/liter; P = 0.002], systolic blood pressure [124.1 (12.1) vs. 122.3 (14.5) mm Hg; P = 0.018], and diastolic blood pressure [73.2 (8.4) vs. 69.7 (8.3) mm Hg; P = 0.005] with omega-3 fatty acids compared with placebo. Omega-3 fatty acids particularly decreased hepatic fat in women with hepatic steatosis, defined as liver fat percentage greater than 5% [18.2 (11.1) vs. 14.8 (9.3)%; P = 0.03].
Conclusions
Omega-3 fatty acid supplementation has a beneficial effect on liver fat content and other cardiovascular risk factors in women with PCOS, including those with hepatic steatosis. Whether this translates into a reduction in cardiometabolic events warrants further study.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.